Interferon alfa-2b is a form of recombinant human interferon used to treat hepatitis B and C infection, genital warts, hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDs-related Kaposi's sarcoma. Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced).
- Mechanism
- Curator reviewed
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
- Primary indication
- For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.Curator reviewed · 9 structured indications
- Formula / weight
- C860H1353N229O255S9 · 19271.0 Da
- First approval
- Canada, 1999 · United States, 1986
- Also known as
- IFN alpha-2B · Interferon alfa 2-b · Interferon alfa 2b · Interferon alfa-2b (recombinant) · Interferon alfa-2b, recombinant
- Code names
- 99210-65-8 · SCH-30500 · YM 14090
- Brand names
Resolves to
What you can answer from here — as of September 12, 2026
Which drugs share a target with Interferon alfa-2b, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account